Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Other Non-current Assets

Long-term assets not reported separately.

Coya Therapeutics, Inc.NASDAQ: COYA

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets turns negative

Q1 FY2026 other non-current assets was -$8.41M, compared with $0 a year earlier.

Context

  • Other non-current assets amounted to 15.8% of total assets at the end of Q1 FY2026, up 15.8 pp from a year earlier.
  • Other non-current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.41M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Other Non-current Assets vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's Mar 2026 other non-current assets of -$8.41M is the lowest of the 11 companies compared; the peer median is $1.53M.
  • Other non-current assets amounts to 15.8% of total assets for COYA, versus a peer median of 1.0%.
COYA Competitors Peer median
Other Non-current Assets for COYA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$12.01M +521.5%—5.3%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$4.1M +22.6%-11.5%1.6%
PLRXPliant Therapeutics, Inc.Mar 2026$3.63M +90.1%+112.4%1.8%
STTKShattuck Labs, Inc.Mar 2026$2.02M +6.7%-22.3%2.0%
WHWKWhitehawk Therapeutics IncMar 2026$1.68M +23.3%-5.9%1.3%
MGNXMacroGenics, Inc.Mar 2026$1.38M -7.7%+0.2%0.6%
IMMXImmix Biopharma, Inc.Mar 2026$185.14K +806.8%+156.9%0.2%
ORMPOramed Pharmaceuticals Inc.Mar 2026$48K -98.9%+371.8%0.0%
CLNNClene Inc.Mar 2026$0 ——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 ——0.0%
COYACoya Therapeutics, Inc.Mar 2026-$8.41M ——15.8%
Peer median (excluding COYA) $1.53M+23.0%+0.2%1.0%

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.34M5.93M32.63M38.34M46.82M
Short-term Investments00000
Net Receivables007.5M730.58K0
Inventory00000
Other Current Assets00000
Total Current Assets4.58M7.18M41.2M44.31M49.94M
Property, Plant & Equipment (Net)120.67K93.31K65.95K38.59K11.23K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets87.18K1.12M000
Total Non-current Assets207.85K1.21M65.95K38.59K11.23K
Total Assets4.79M8.4M41.26M44.35M49.95M
Account Payables857.57K1.82M1.16M1.59M1.06M
Short-term Debt00000
Tax Payables00723.85K00
Deferred Revenue00923.11K848.29K1.2M
Other Current Liabilities00000
Total Current Liabilities1.15M3.82M5.05M3.82M5.87M
Long-term Debt012.97M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00574.69K945.45K1.05M
Other Non-current Liabilities00000
Total Non-current Liabilities012.97M574.69K945.45K1.05M
Total Liabilities1.15M16.79M5.63M4.77M6.92M
Common Stock2592591.44K1.67K2.09K
Retained Earnings(5.62M)(17.87M)(25.86M)(40.74M)(61.96M)
Accumulated OCI00000
Other Stockholders Equity00(11.25K)00
Minority Interest00000
Total Equity3.64M(8.39M)35.64M39.58M43.03M
Total Debt012.97M000
Net Debt(4.34M)7.03M(32.63M)(38.34M)(46.82M)

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.